GUCY2C and colorectal carcinoma: Bispecific antibodies and CAR-T or CAR-NK cell therapies targeting CRC-associated antigens (CEA, GUCY2C, Claudin-18.2) are emerging tools under clinical evaluation for MSS CRC (Ma N. et al., 2025; Yang et al., 2024).